EUVIMEDEUVIMED entdecken
Crossref

Trastuzumab Deruxtecan Is Active in Desmoplastic Small Round Cell Tumor

Emily K. Slotkin, Tamar Y. Feinberg, Umesh K. Bhanot, Anita Price, Neeta Pandit-Taskar, Dylan Domenico, Gerlad Behr, Narasimhan P. Agaram, Cristina R. Antonescu, Meera Hameed, Konstantinos Linos, Carla Saoud und 19 weitere

JCO Oncology Advances · 2026-01 · 3 (1)

DOI: 10.1200/oa-25-00141 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Advances, 2026-01. Verfasst von Emily K. Slotkin und 30 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Desmoplastic small round cell tumor (DSRCT) is a rare sarcoma which remains almost universally fatal despite multimodality therapy. Human epidermal growth factor receptor 2 (HER2) has been identified as a potential therapeutic target prompting HER2-specific investigations and subsequent off-label treatment with fam-trastuzumab deruxtecan (T-DXd) in our DSRCT clinical cohort. METHODS Fifty-two and 61 DSRCT patient samples were analyzed by immunohistochemical (IHC) assays and RNAseq, respectively. In addition, 19 patients at a single institution with DSRCT in need of therapy underwent IHC testing and RNAseq when feasible and received off-label T-DXd (monotherapy [n = 14], alternating with another agent [n = 2], concomitantly in combination [n = 2]; measurable disease [n = 17], adjuvant setting [n = 2]). RESULTS HER2 expression levels by RNAseq were analyzed in the context of 346 patients with solid tumor and 23 histologies, with DSRCT having the third highest HER2 expression level overall and a median transcripts per million (TPM) expression level of 41.8 (range, 6.3-116.3). While TMA IHC analyses noted minimal HER2 IHC positivity using 4B5, IHC with clones 29D8 and CB11 uncovered 8.7- to 12.7-fold more HER2 reactivity, respectively. All 17 patients with measurable disease experienced clinical benefit (stable disease or partial response [PR]) with minimal toxicity. In addition, 9 of 17 patients achieved a RECIST PR (53% overall response rate). The response rate did not correlate with available IHC or RNAseq data, and some patients with no membranous IHC expression achieved PR. CONCLUSION These data show that T-DXd is active in DSRCT and support the planned biomarker-agnostic formal clinical trial with the Children's Oncology Group.

Zitieren

APA

Slotkin, E. K., Feinberg, T. Y., Bhanot, U. K., Price, A., Pandit-Taskar, N., Domenico, D., Behr, G., Agaram, N. P., Antonescu, C. R., Hameed, M., Linos, K., Saoud, C., Papaemmanuil, E., Cruz, F. S. D., Burke, C. M., Ortiz, M. V., Wexler, L. H., Pavisic, J., Meyers, P. A., …, & Reed, D. R. (2026). Trastuzumab Deruxtecan Is Active in Desmoplastic Small Round Cell Tumor. JCO Oncology Advances. https://doi.org/10.1200/oa-25-00141

Vancouver

Slotkin EK, Feinberg TY, Bhanot UK, Price A, Pandit-Taskar N, Domenico D, et al. Trastuzumab Deruxtecan Is Active in Desmoplastic Small Round Cell Tumor. JCO Oncology Advances. 2026. doi:10.1200/oa-25-00141

BibTeX
@article{Slotkin2026,
  author = {Slotkin, Emily K. and Feinberg, Tamar Y. and Bhanot, Umesh K. and Price, Anita and Pandit-Taskar, Neeta and Domenico, Dylan and Behr, Gerlad and Agaram, Narasimhan P. and Antonescu, Cristina R. and Hameed, Meera and Linos, Konstantinos and Saoud, Carla and Papaemmanuil, Elli and Cruz, Filemon S. Dela and Burke, Chelsey M. and Ortiz, Michael V. and Wexler, Leonard H. and Pavisic, Jovana and Meyers, Paul A. and Espinosa-Cotton, Madelyn and Berman, Laney and Diamantis, Kleoniki and Hennessy, Jessie and Kelly, Paulette and Sauerhaft, Talia and Swanson, Kelly and Voccola, Jamie and Tap, William D. and Blender, Julia L. Glade and Kung, Andrew L. and Reed, Damon R.},
  title = {Trastuzumab Deruxtecan Is Active in Desmoplastic Small Round Cell Tumor},
  journal = {JCO Oncology Advances},
  year = {2026},
  doi = {10.1200/oa-25-00141}
}
Kostenlos starten →